Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases

Annals of Surgery

Volumn 246, Issue 5, 2007, Pages 806-814

  Malik, Hassan Z ^a   Prasad, K Rajendra ^a   Halazun, Karim J ^a   Aldoori, Amir ^a   Al Mukhtar, Ahmed ^a   Gomez, Dhanwant ^a   Lodge, J Peter A ^a   Toogood, Giles J ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATION; LIVER METASTASIS; LIVER RESECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUTROPHIL COUNT; PATHOLOGY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LEUKOCYTE COUNT; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 35648969531     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318142d964     Document Type: Article

References (64)

1. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759-766.
2. Scheele J, Stangl R, Altendorf-Hofmann A, et al. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery. 1991;110:13-29.
3. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818-825; discussion 825-827.
4. Fernandez FG, Drebin JA, Linehan DC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004;240:438-447; discussion 447-450.
5. Hughes K, Scheele J, Sugarbaker PH. Surgery for colorectal cancer metastatic to the liver. Optimizing the results of treatment. Surg Clin North Am. 1989;69:339-359.
6. Rees M, Plant G, Bygrave S. Late results justify resection for multiple hepatic metastases from colorectal cancer. Br J Surg. 1997;84:1136-1140.
7. Steele G Jr, Bleday R, Mayer RJ, et al. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J Clin Oncol. 1991;9:1105-1112.
8. Sugihara K, Hojo K, Moriya Y, et al. Pattern of recurrence after hepatic resection for colorectal metastases. Br J Surg. 1993;80:1032-1035.
9. Ohlsson B, Stenram U, Tranberg KG. Resection of colorectal liver metastases: 25-year experience. World J Surg. 1998;22:268-276; discussion 276-277.
10. Okano K, Yamamoto J, Kosuge T, et al. Fibrous pseudocapsule of metastatic liver tumors from colorectal carcinoma. Clinicopathologic study of 152 first resection cases. Cancer. 2000;89:267-275.
11. Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241:715-722; discussion 722-724.
12. Jaffe BM, Donegan WL, Watson F, et al. Factors influencing survival in patients with untreated hepatic metastases. Surg Gynecol Obstet. 1968;127:1-11.
13. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905-914.
14. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-2947.
15. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet. 2000;355:1041-1047.
16. Memon MA, Beckingham IJ. Surgical resection of colorectal liver metastases. Colorectal Dis. 2001;3:361-373.
17. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309-318; discussion 318-321.
18. Kemeny N, Jarnagin W, Paty P, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol. 2005;23:4888-4896.
19. Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol. 2001;8:347-353.
20. Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224:509-520; discussion 520-522.
21. Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol. 1999;10:663-669.
22. Fernandez FG, Ritter J, Goodwin JW, et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg. 2005;200:845-853.
23. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065-2072.
24. Simmonds PC, Primrose JN, Colquitt JL, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94:982-999.
25. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539-545.
26. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.
27. McMillan DC, Wotherspoon HA, Fearon KC, et al. A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery. Am J Surg. 1995;170:319-322.
28. Gunter MJ, Stolzenberg-Solomon R, Cross AJ, et al. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res. 2006;66:2483-2487.
29. McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg. 2003;90:215-219.
30. Canna K, McArdle PA, McMillan DC, et al. The relationship between tumor T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer. 2005;92:651-654.
31. Walsh SR, Cook EJ, Goulder F, et al. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005;91:181-184.
32. Couinaud C. Not available. Presse Med. 1954;62:709-712.
33. Jamison RL, Donohue JH, Nagorney DM, et al. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg. 1997;132:505-511.
34. Liu CL, Fan ST, Lo CM, et al. Hepatic resection for colorectal liver metastases: prospective study. Hong Kong Med J. 2002;8:329-333.
35. Kato T, Yasui K, Hirai T, et al. Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum. 2003;46:22-31.
36. Bramhall SR, Gur U, Coldham C, et al. Liver resection for colorectal metastases. Ann R Coll Surg Engl. 2003;85:334-339.
37. Belghiti J, Hiramatsu K, Benoist S, et al. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg. 2000;191:38-46.
38. Fortner JG, Blumgart LH. A historic perspective of liver surgery for tumors at the end of the millennium. J Am Coll Surg. 2001;193:210-222.
39. Malik HZ, Hamady ZZR, Adair R, et al. Prognostic influence of multiple hepatic metastases from colorectal cancer. Eur J Surg Oncol. 2007;33:468-473.
40. Nishio H, Hamady ZZR, Malik HZ, et al. Outcome following repeat hepatectomy for colorectal liver metastases-analysis of prognostic factors and influence of the type of first hepatectomy. Eur J Surg Oncol. In press.
41. Hamady ZZR, Cameron I, Wyatt J, et al. Resection margin in patients undergoing hepatectomy for colorectal liver metastasis: a critical appraisal of the 1 cm rule. Eur J Surg Oncol. 2006;32:557-563.
42. Crumley ABC, McMillan DC, McKernan M, et al. An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer. 2006;94:1568-1571.
43. Nozoe T, Saeki H, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg. 2001;182:197-201.
44. Xavier P, Belo L, Beires J, et al. Serum levels of VEGF and TNF-a and their association with C-reactive protein in patients with endometriosis. Arch Gynecol Obstet. 2006;273:227-231.
45. Tanigawa N, Amaya N, Matsumura M, et al. Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J Clin Oncol. 1997;15:826-832.
46. Vidal-Vanaclocha F, Fantuzzi G, Mendoza L, et al. IL-18 regulates IL-1b-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci USA. 2000;97:734-739.
47. Okano K, Maeba T, Modoguchi A, et al. Lymphocytic infiltration surrounding liver metastases from colorectal cancer. J Surg Oncol. 2003;82:28-33.
48. Kusumanto YH, Dam WA, Hospers GA, et al. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 2003;6:283-287.
49. Ward J, Robinson PJ, Guthrie JA, et al. Liver metastases in candidates for hepatic resection: comparison of helical CT and gadolinium- and SPIO-enhanced MR imaging. Radiology. 2005;237:170-180.
50. Pohlen U, Rieger H, Mansmann U, et al. Hepatic arterial infusion (HAI). Comparison of 5-fluorouracil, folinic acid, interferon alpha-2b and degradable starch microspheres versus 5-fluorouracil and folinic acid in patients with non-resectable colorectal liver metastases. Anticancer Res. 2006;26:3957-3964.
51. Kohne CH, Cunningham D, Di Costanzo F, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol. 2003;14:1450-1451.
52. Ho-Wing M, Ma B, Mok-Tony, et al. Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group. Med-Oncol. 2005;22:303-312.
53. Cunningham D, Pyrhonen S, James RD, et al. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998;352:1413-1418.
54. Chen L, Liu Y, Li GG, et al. Quality of life in patients with liver cancer after operation: a 2-year follow-up study. Hepatobiliary Pancreat Dis Int. 2004;3:530-533.
55. Gazelle GS, McMahon PM, Beinfeld MT, et al. Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection. Radiology. 2004;233:729-739.
56. Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to resection for multiple colorectal metastases? Ann Surg. 2004;240:1052-1064.
57. Halazun KJ, Aldoori A, Malik HZ, et al. Elevated preoperative neutrophil to lymphocyte ratio confers poor outcome and increased recurrence rate after resection for colorectal liver metastases. Eur J Surg Oncol. In press.
58. Fenwick SW, Toogood GJ, Lodge JP, et al. The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Gastroenterology. 2003;125:716-729.
59. Chalmers CR, Wilson DJ, Ward J, et al. Antiangiogenic activity of the selective cyclooxygenase 2 inhibitor rofecoxib in human colorectal cancer liver metastases. Gut. 2006;55:1058-1059.
60. Yamauchi T, Watanabe M, Hasegawa H, et al. The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer. Anticancer Res. 2003;23:245-249.
61. Lonneux M, Reffad AM, Detry R, et al. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer. Eur J Nucl Med Mol Imaging. 2002;29:915-921.
62. Veit P, Antoch G, Stergar H, et al. Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results. Eur Radiol. 2006;16:80-87.
63. Pelosi E, Messa C, Sironi S, et al. Value of integrated PET/CT for lesion localization in cancer patients: a comparative study. Eur J Nucl Med Mol Imaging. 2004;31:932-939.
64. Khan S, Tan YM, John A, et al. An audit of fusion CT-PET in the management of colorectal liver metastases. Eur J Surg Oncol. 2006;32:564-567.